Briefcases -- Drugs -- TASIGNA (nilotinib hydrochloride monohydrate) by Novartis AG/Novartis Pharmaceuticals, Inc.

TASIGNA (nilotinib hydrochloride monohydrate) by Novartis AG/Novartis Pharmaceuticals, Inc.

Case Files
News
Committees
Request a Document
Request
Search Within Briefcase

Folders

  1. Single Event Case Filings
  2. Media References
  3. FDA Regulatory Materials

Quick Access

  1. TASIGNA (nilotinib) Lauris vs Novartis USDC ED California Initial Complaint (Wrongful Death) (March 2016)
  2. TASIGNA (nilotinib) Lauris vs Novartis USDC ED California Novartis AG's Trial Brief (December 29, 2017)
  3. TASIGNA (nilotinib) Lauris vs Novartis USDC ED California Order Denying Foreign Jurisdiction (March 15, 2017)
  4. TASIGNA (nilotinib) Lauris vs Novartis USDC ED California Plaintiffs' Expert Witness Reports and Disclosures (June 1, 2017)
  5. TASIGNA (nilotinib) Lauris vs Novartis USDC ED California Plaintiffs' Expert Report Exhibit N by Klaus Hoffman (June 5, 2017)
  6. TASIGNA (nilotinib) Lauris vs Novartis USDC ED California Plaintiffs' Disclosure of Expert Attachments (June 30, 2017)
  7. TASIGNA (nilotinib) Lauris vs Novartis USDC ED California Novartis AG's Expert Witness Reports and Disclosures (June 30, 2017)
  8. TASIGNA (nilotinib) Lauris vs Novartis USDC ED California Novartis AG's Expert Witness Reports and Disclosures Part II (June 30, 2017)